BioAdaptives Inc (BDPT)

[carusso]

Hope so, too!

[stervc]

carusso...

I'm just holding and hoping that the CEO given his qualifications would not be here keeping BDPT current with it SEC filing if he had no plan to eventually move forward.

v/r
Sterling

[carusso]

Ok, thx

[pinkslipjunkie]

I don't know what will happen here...sorry I can't give you a better insight

[carusso]

Care to share your views on the future of this company?

[carusso]

Thanks for posting that…

Does this still have a detectable pulse?

[DK11]

Hopefully INTHEKNOW1 got rid of all his shares coming to an end now.

[LJ-Bodhi]

More dilution with over a billion shares now. More losses, no money, no prospects. Downward trend likely to continue.

[pinkslipjunkie]

It looks like they pulled through on the 10Q.
https://ih.advfn.com/stock-market/USOTC/bioadaptives-pk-BDPT/stock-news/93882024/form-10-q-quarterly-report-sections-13-or-15d

[WorkinGreen]

Aren’t you a sight for sore eyes. Good to see you on board.

[I-Glow]

That is hilarious - they have a new auditor because Borgers is a prohibited service provider.

"SEC Charges Audit Firm BF Borgers with Fraud"

The question is why did BDPT use a fraudulent auditor?

You didn't mention that BDPT is listed as a Shell Risk.

The Securities Counsel Donald Keer doesn't have many reputable clients on the OTC.

IG

[WorkinGreen]

That would be ideal

[starkd748]

Give me no bid .0001s

[DK11]

This will soon go to 3 then 2.

[WorkinGreen]

Thanks stervc

$BDPT

[stervc]

BDPT 8-K New Auditor...

BDPT 8-K New Auditor...

https://www.otcmarkets.com/filing/html?id=17535806&guid=RrQ-k619PyECJth
On May 11, 2024, BioAdaptives’ Board approved the appointment of Boladale Lawal & Co as the Company’s new independent registered PCAOB firm, effective immediately to perform independent audit services for the fiscal year ending December 31,2024 and also the reviews of its quarterly reporting of 2024. Furthermore, Boladale Lawal & Co. will audit the balance sheet of the Company as of December 31, 2023, and the related statements of operations, stockholders’ equity and cash flows for the year then ended. Based upon the audits, Boladale Lawal & Co. will issue a written report on the Company’s financial statements as well.

v/r
Sterling

[Rainer]

http://archive.fast-edgar.com/20240514/AE2ZL62CZ222RZZ2222Q2Z4FI4GCZC228962/

[Tim36]

Knowing this was occurring?

[KeepItRealistic]

$BDPT used 1800 Diagonal Lending, LLC extensively…

U.S. SECURITIES AND EXCHANGE COMMISSION

Litigation Release No. 25995 / May 7, 2024
Securities and Exchange Commission v. Power Up Lending Ltd., et al., No. 1:24-cv-03498 (S.D.N.Y. filed May 7, 2024)
SEC Sues Curt Kramer and Three of His Businesses for Acting as Unregistered Securities Dealers

The Securities and Exchange Commission announced today charges against Curt Kramer of Jericho, New York, and his wholly owned businesses Power Up Lending Ltd., Geneva Roth Remark Holdings, Inc., and 1800 Diagonal Lending, LLC (formerly known as Sixth Street Lending LLC), for operating as unregistered securities dealers.

The SEC's complaint, filed in the United States District Court, Southern District of New York, alleges that since at least January 2018 through at least March 2023, Kramer and his companies engaged in the business of purchasing convertible securities from penny stock issuers, converting those securities into common stock at a large discount from the prevailing market price, and quickly selling the newly issued shares into the market for a profit. The SEC's complaint alleges that the Defendants purchased nearly 2,000 convertible securities from about 325 microcap stock issuers, converted the securities into more than 100 billion newly-issued shares of common stock, rapidly sold the newly issued shares into the market, and generated millions of dollars in revenues and profits. As alleged, Kramer and his companies were not registered as dealers with the SEC or associated with a registered broker-dealer, as their activities required them to do.

The SEC's complaint charges Kramer, Power Up, Geneva Roth, and 1800 Diagonal with violating the dealer registration provision of Section 15(a)(1) of the Securities Exchange Act of 1934 ("Exchange Act"), and also alleges Kramer is liable as a control person of his companies pursuant to Section 20(a) of the Exchange Act. The SEC seeks a permanent injunction, disgorgement of ill-gotten gains plus prejudgment interest, civil penalties, a penny stock bar, and other equitable relief.

The SEC's investigation was conducted by Stephen LeBlanc and supervised by Lisa Deitch and Stacy Bogert. The litigation will be led by Suzanne Romajas, Daniel Lloyd, and Stephen LeBlanc, and supervised by Christopher Bruckmann.

[02opida]

last pr BioAdaptives, Inc. Announces NaturaComplete, an All-In-One Supplement to Optimize Its AI-Based FYO Obesity Management System

[Dark Roast]

You don’t know. Keep Guessing.

[DK11]

Moving very slowly and now quiet.

[Mutat]

This seems to be moving again.

[INTHEKNOW1]

SOMETHING TELLS ME PR COMMETH!

[INTHEKNOW1]

5's are golden IMO. Patience will pay bigly for those who accumulate trips.

[AverageJoe]

Their App, Fit Your Outfit, could potentially generate a lot of profit or the app itself could be one of many in a portfolio of health related apps that Bioadaptives owns and operates. Apps typically generate good amounts of passive and residual income while maintenance is almost non-existent. I bet we hear something soon regarding future endeavors in this realm. I'm done adding here but if they come out with some solid news I'll be buying more...

[DK11]

Looks like the swing is breaking

[m_m007]

This will be out of trips in one day, watch. Tons of trip going to 003plus. Got my ticket

[carusso]

Read more about what they are doing, and reach out to them where you have questions.

[AverageJoe]

My patience wearing thin here though on this Friday, gotta admit I assumed this would be out of trips by now but that was with a hope that management was working diligently behind the scenes. Scary to have tens of thousands tied up in this ticker that hasn't panned out. Does management even care? Are they working on anything of substance?

[AverageJoe]

Adding 5's and 6's, somebody knows something ;)

[INTHEKNOW1]

ADDING .0005's MYSELF... BEST TRIP ON BOARD😉

[Hymeeto]

Looks like ZALMY worked his BAG MAGIC on this ticker now too. Worst front loader PUMP and DUMPER there is...

[Thehustle]

Got a few chasers today then they will come back and buy higher when we are running after losing on the stock they chased.. lol

Story sound familiar?

[Ribo]

https://twitter.com/OtcUpdates/status/1779961403903783306

[Thehustle]

Folks will add more at the 7 break

[JBZ]

Looking good here on Technical Stand Point. Don't know much of the Fundamental Catalyst's here, But Techs are an go.

BDPT!$!!$$$!!!!!

[dig4gold]

Yesterday there was so much interest end of day… today nothing. I don’t know what’s happening here.

[koolmc]

surge in volume because of other subbies going

[INTHEKNOW1]

END OF WEEK POP IS EXACTLY WHAT THE DOCTOR ORDERED! HEAVY ACCUMULATION IS NOT AN ACCIDENT. IMO, SOMETHING COMETH! HOPE YOUR LOADED.

[Penny2Dime]

Accumulation!

[Thehustle]

Hope yall didn’t flip out early. Let’s see subs!

[dig4gold]

I’m not sure but definitely there was lots of interest today….went from very red to a strong close.

[INTHEKNOW1]

Damn whats up with the buying surge suddenly?

[AverageJoe]

$BDPT about to fly in my opinion!: 12. SUBSEQUENT EVENTS



On October 11 2023, the Company filed a new Reg A for the marketing of 250,000,000 common shares at a price range of $0.001 to $0.003, to be determined after qualifying. This new Reg A is to provide additional funding for the marketing for BioAdaptives itself, and also for its wholly owned subsidiary, LiveStock Impact Inc, The Company is looking to expand its range of targeted human health supplements. It is also focused on the marketing effort of LiveStock Impact, Inc and its wholesale activities as well as its interest in botanical drugs. Towards this end, since October, the Company has been working with a professional entity on its press releases and marketing promotions. It expects to intensify its marketing outreach in the next two quarters. In January 2024, the Company launches an innovative food Lab for the development of treats and supplement powder for human, equine and canine. The initial trials were conducted in an established kitchen facility. In January 2024, BioAdaptives signed a Distributor’s agreement with PIXELCANDO SL to distribute FitYourOutfit® (FYO) product in North America. This is a low-cost AI smart phone app body composition tracking system to detect unwanted muscle mass loss reported with obesity management and also fat loss. In conjunction with its BodyShape Lab division and the AI FYO system product, the Company acquired the distribution rights of an All-In-One dietary supplement formula,, NaturaComplete™.This new formula provides a comprehensive array of over 70 vitamins, mineral, amino and fatty acids, trace minerals and other nutrients to support general health and obesity management activities. It is expected that NaturaComplete™ will be marketed within the first 2 quarters of 2024 together with Pluripain PMS™, which is designed to help manage the symptoms associated with the menstrual cycle and VeganHepplus™, a liver support supplement. Two equine products: Equine All-In-On Extreme and Equine All-In-One Extreme Booster will both be actively launched in the first two quarters of 2024 for competition and performance horses.

[LJ-Bodhi]

The OS is not maxed out. Read page 41 of the annual report:

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table sets forth certain information as of December 31, 2023, regarding the number of shares of Common Stock beneficially owned by (i) each person or entity known to us to own more than five percent of our Common Stock; (ii) each of our Named Executive Officers; (iii) each of our directors; and (iv) all of our executive officers and directors as a group. The percentages are based on 895,750,225 total outstanding Shares as of December 31, 2023.

1.25 billion AS
895 million OS

200 million shelf registration still being actively marketed to sell new shares.

One lender who has converted around 600m shares and dumped on the market. Still converting and dumping. Chart of all conversions is on pages 15 and 16. Dilution is ongoing and AS will likely be raised again soon.

https://www.otcmarkets.com/filing/html?id=17441285&guid=O_Q-kF378EKfJth#BDPT_10K_HTM_I12

[Thehustle]

Exactly news and updates are cherry on top and I bet we see news coming. Especially with maxed out SS

[powerbattles]

With the company's outstanding shares half of ILST's, and ILST gaining 100% today, +400% in two days. There's no reason we can't move higher from $0.0006.

[Thehustle]

Based on the share structure and alone and it being maxed out plus most likely news coming this is definitely in my opinion going back to subs

[powerbattles]

Look at my past posts to find my opinion—all the details are there. As of now, the fundamentals have shifted. When I initially discovered the stock, the outstanding shares were less than 300 million, and it had a strong run at that time.

"On September 8, 2023, the Company registered its Livestock Impact Division as a wholly owned subsidiary in Nevada with 200,000,000 shares authorized and 10,000,000 preferred shares.

The Livestock Impact Division is supposed to spin-off, in a spin-off, the parent company declares a special dividend payable in shares of the subsidiary company, but they can't execute the plan. If they can't follow through with the spin-off, and market the products which was the primary reason I invested in the stock, then I can't do much about it. I informed everyone that I was giving them until December to finalize the spin-off, and if they couldn't, I would have to move on. I sold my last share in Feb.

At this point the o/s near max out which is for the trip 0 I think is still very low. For the short term, people can easily flip 30% to 100% profit if they buy at this current price .0004 to .0006. In the long term. The company needs working capital at this time the only way to fund the company is to dilute the shares. On October 11, 2023, the Company filed a Form 1-A with the Securities Exchange Commission covering a plan to sell up to 250,000,000 shares of common stock for prices between $0.001-0.003. This filing is ongoing as indicated it will be challenging to move the share above the .001 mark.

Yet, there remains hope for them if they can successfully raise additional funds without diluting the shares and effectively market their products to consumers. GLTA!

Effective April 2023, FCBR Therapy Division has been appointed its exclusive Distributor for all LiveStock Impact’s products; the Company also negotiated with the supplier for the exclusive marketing rights to these products from the non-exclusive license it has held since June 2022. In this first quarter of the exclusive wholesale agreement, its wholesale volume has surpassed the past 9 months total by 400%. Granted due to the switch from retail to wholesale the margins are much tighter, but we believe in 2024, the expanded sales will greatly benefit this wholly owned subsidiary and will justify its eventual independence.

The Company is also negotiating distribution rights to three additional human products: Pluripain PMS™, which is designed to help manage the symptoms associated with the menstrual cycle; VeganHepplus™, a liver support supplement; as well as NaturaComplete™, an All-In-One dietary supplement formula with over 70 vitamins, mineral, amino and fatty acids, trace minerals and other nutrients to support general health and obesity management activities. These three new products are expected to be in market within first six months of 2024.